Skip to main navigation
TCR2 Staging

Corporate Menu & Investor Relations

Contact Patients
Mission Leadership Community
The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications
Overview TC-210 TC-110 Pipeline
Press Releases In the News Awards
Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs
Careers
investors.jpg
TCR2 Investors

Corporate Menu & Investor Relations

About Us Mission Leadership Community Technology The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications Programs Overview TC-210 TC-110 Pipeline News Press Releases In the News Awards Investors Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs Careers Careers Contact Patients

Presentations

Presentations

Corporate Presentation - January
TCR2 Corporate Presentation - January 2021 4.1 MB
Interim Clinical Data from Gavo cel (TC 210) Patients
Interim Clinical Data from Gavo cel (TC 210) Patients 1.4 MB
TC-210 Phase 1 Interim Data
TC-210 Phase 1 Interim Data 5.3 MB
June 2020 - AACR Virtual Annual Meeting II
A Chimeric PD1-CD28 Switch Receptor Enhances the Activity of TRuC-T Cells 2.7 MB
Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuCâ„¢) T Cells 11.3 MB
February 2020 - Keystone Symposia
Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuCTM) T Cells 5.1 MB
April 2019 - AACR
Preclinical Evaluation of TC-110: CD19-Specific T Cell Receptor (TCR) Fusion Construct (TRuCTM) T Cells for the Treatment of Hematologic Malignancy 4.5 MB
Preclinical Evaluation of TC-210: A Mesothelin-Specific T Cell Receptor (TCR) Fusion Construct (TRuCTM) T Cells for the Treatment of Solid Tumors 7.2 MB

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
TCR2
 

100 Binney Street, Suite 710
Cambridge, MA 02142
617.949.5200

TERMS OF USE

Corporate Menu & Investor Relations

About Us
Technology
Programs
News
Investors
Careers
Contact
Patients